ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Indianapolis, IN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Ovarian Epithelial Carcinoma

Triple Negative Breast Cancer trials near Indianapolis, IN, USA:

Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers

and to evaluate the efficacy of this combination in advanced HER2 negative breast cancer that is triple negative...

Active, not recruiting
TNBC - Triple-Negative Breast Cancer
Drug: Talazoparib
Drug: Gedatolisib

Phase 1, Phase 2

Kari Wisinski

Indianapolis, Indiana, United States and 4 other locations

Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer (PERSEVERE)

This is a 3-arm study stratified by plasma ctDNA. Patients with residual TNBC disease after pre-operative therapy will be assigned to 1 of 3 Arms bas...

Active, not recruiting
Breast Cancer
Triple Negative Breast Cancer
Drug: Inavolisib
Drug: Talazoparib

Phase 2

Bryan Schneider, MD

Indianapolis, Indiana, United States and 12 other locations

SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers

of care (SOC) chemotherapy monotherapy vs. SOC chemotherapy combined with tocilizumab in in Black and non-Black patients with metastatic triple...

Enrolling
Estrogen-receptor-low Breast Cancer
Metastatic Breast Cancer
Drug: Tocilizumab
Drug: SOC Chemotherapy

Phase 2

Kathy Miller

Indianapolis, Indiana, United States and 3 other locations

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)

or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...

Enrolling
Triple Negative Breast Cancer
Drug: Capecitabine
Drug: Sacituzumab govitecan-hziy (SG)

Phase 3

Gilead Sciences
Gilead Sciences

Indianapolis, Indiana, United States of America and 176 other locations

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

levels in combination with chemotherapeutic agents in the first- and second-line treatment of participants with locally advanced/metastatic triple...

Enrolling
Locally Advanced Breast Cancer
Metastatic Triple Negative Breast Cancers
Drug: BNT327 Equivalent Q3W Dose
Drug: BNT327 Dose Level 1 (DL2)

Phase 2

BioNTech
BioNTech

Indianapolis, Indiana, United States and 63 other locations

A Study of SGN-B7H4V in Advanced Solid Tumors

cancers.* Part D will find out if and how much SGN-B7H4V can be given with pembrolizumab.* Part E will use the amount found in Part D to fi ...

Active, not recruiting
Ovarian Neoplasms
Hormone Receptor Positive Breast Neoplasms
Drug: SGN-B7H4V
Drug: Pembrolizumab

Phase 1

Seagen
Seagen

Indianapolis, Indiana, United States and 18 other locations

Study of LP-184 in Patients with Advanced Solid Tumors

The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors w...

Enrolling
TNBC - Triple-Negative Breast Cancer
Advanced Solid Tumor
Drug: LP-184
Drug: Spironolactone

Phase 1, Phase 2

Lantern Pharma

Indianapolis, Indiana, United States and 8 other locations

TTX-080 HLA-G Antagonist in Subjects with Advanced Cancers

including metastatic colorectal cancer (mCRC) patients....

Enrolling
Cancer
Drug: cetuximab
Drug: FOLFIRI

Phase 1

Tizona Therapeutics

Indianapolis, Indiana, United States and 38 other locations

A Phase I/II Study of VLS-1488 in Subjects with Advanced Cancer

This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers...

Enrolling
Squamous Non-small-cell Lung Cancer
Advanced Solid Tumor
Drug: VLS-1488

Phase 1, Phase 2

Volastra Therapeutics

Indianapolis, Indiana, United States and 11 other locations

Locations recently updated

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

The study will determine the recommended Phase 2 dose (RP2D) of livmoniplimab (ABBV-151) administered as monotherapy and in combination with budigali...

Enrolling
Advanced Solid Tumors Cancer
Drug: Livmoniplimab
Drug: Budigalimab

Phase 1

AbbVie
AbbVie

Indianapolis, Indiana, United States and 59 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems